静脉注射纳西他单抗治疗复发/难治性神经母细胞瘤儿童的临床应用

IF 0.8 4区 医学 Q4 HEMATOLOGY
Iris Fried, Michael Weintraub, Dalia Waldman, Shoshana Revel-Vilk
{"title":"静脉注射纳西他单抗治疗复发/难治性神经母细胞瘤儿童的临床应用","authors":"Iris Fried, Michael Weintraub, Dalia Waldman, Shoshana Revel-Vilk","doi":"10.1097/MPH.0000000000003081","DOIUrl":null,"url":null,"abstract":"<p><p>The anti-GD2 antibody Naxitamab requires complicated pain management due to significant adverse effects (AEs). Herein, we report the safety and feasibility of a simplified administration protocol. Between November 2021 and July 2023, 102 Naxitamab infusions were administered at Shaare Zedek Hospital with ketamine as the only analgesic drug during Naxitamab infusion. Pain was controlled in all the cases. Other grade 3-4 AEs, occurred in 10/102 infusions (10%), and none of the patients stopped Naxitamab due to infusion-related AEs. Single-agent ketamine is safe and effective for Naxitamab-infusion-related pain. Thus, its use is feasible in multiple clinical settings. Significant infusion-related AEs after the completion of the 3rd treatment cycle are rare.</p>","PeriodicalId":16693,"journal":{"name":"Journal of Pediatric Hematology/Oncology","volume":"47 6","pages":"e282-e284"},"PeriodicalIF":0.8000,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Real-life Use of IV Naxitamab for Children With Relapsed/Refractory Neuroblastoma.\",\"authors\":\"Iris Fried, Michael Weintraub, Dalia Waldman, Shoshana Revel-Vilk\",\"doi\":\"10.1097/MPH.0000000000003081\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>The anti-GD2 antibody Naxitamab requires complicated pain management due to significant adverse effects (AEs). Herein, we report the safety and feasibility of a simplified administration protocol. Between November 2021 and July 2023, 102 Naxitamab infusions were administered at Shaare Zedek Hospital with ketamine as the only analgesic drug during Naxitamab infusion. Pain was controlled in all the cases. Other grade 3-4 AEs, occurred in 10/102 infusions (10%), and none of the patients stopped Naxitamab due to infusion-related AEs. Single-agent ketamine is safe and effective for Naxitamab-infusion-related pain. Thus, its use is feasible in multiple clinical settings. Significant infusion-related AEs after the completion of the 3rd treatment cycle are rare.</p>\",\"PeriodicalId\":16693,\"journal\":{\"name\":\"Journal of Pediatric Hematology/Oncology\",\"volume\":\"47 6\",\"pages\":\"e282-e284\"},\"PeriodicalIF\":0.8000,\"publicationDate\":\"2025-08-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Pediatric Hematology/Oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1097/MPH.0000000000003081\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/7/24 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q4\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Pediatric Hematology/Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/MPH.0000000000003081","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/7/24 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

抗gd2抗体Naxitamab由于严重的不良反应(ae)需要复杂的疼痛管理。在此,我们报告了一种简化给药方案的安全性和可行性。在2021年11月至2023年7月期间,Shaare Zedek医院进行了102次纳西他抗输注,氯胺酮作为纳西他抗输注期间唯一的镇痛药物。所有病例的疼痛都得到了控制。其他3-4级不良事件发生在10/102次输注中(10%),没有患者因输注相关不良事件停用纳西他单抗。单药氯胺酮治疗纳西他单抗输注相关疼痛安全有效。因此,它的使用在多种临床设置是可行的。在完成第3个治疗周期后,显著的与输注相关的不良反应是罕见的。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Real-life Use of IV Naxitamab for Children With Relapsed/Refractory Neuroblastoma.

The anti-GD2 antibody Naxitamab requires complicated pain management due to significant adverse effects (AEs). Herein, we report the safety and feasibility of a simplified administration protocol. Between November 2021 and July 2023, 102 Naxitamab infusions were administered at Shaare Zedek Hospital with ketamine as the only analgesic drug during Naxitamab infusion. Pain was controlled in all the cases. Other grade 3-4 AEs, occurred in 10/102 infusions (10%), and none of the patients stopped Naxitamab due to infusion-related AEs. Single-agent ketamine is safe and effective for Naxitamab-infusion-related pain. Thus, its use is feasible in multiple clinical settings. Significant infusion-related AEs after the completion of the 3rd treatment cycle are rare.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
1.90
自引率
8.30%
发文量
415
审稿时长
2.5 months
期刊介绍: ​Journal of Pediatric Hematology/Oncology (JPHO) reports on major advances in the diagnosis and treatment of cancer and blood diseases in children. The journal publishes original research, commentaries, historical insights, and clinical and laboratory observations.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信